Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

rhPTH (1-84)

Approved · mab · Hypoparathyroidism

rhPTH (1-84) for Hypoparathyroidism is a Approved program (mab) at Takeda with 3 ClinicalTrials.gov record(s).

← All Takeda projects Approved mab completed

Internal code SHP634-401

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Approved
Modality
mab
Indication
Hypoparathyroidism
Status
completed
Trials
3